Fri, Dec 26, 2014, 11:36 AM EST - U.S. Markets close in 4 hrs 24 mins

Recent

% | $
Quotes you view appear here for quick access.

Advanced Medical Isotope Corporation Message Board

  • macd_chart macd_chart Jan 11, 2014 11:42 AM Flag

    ADMD Jump tied to Nordion Comments.

    On Thursday Nordian (NDZ) released Fourth Quarter and Fiscal 2013 results in which the company detailed performance of their Medical Isotope business. In the company’s release the company said that “Contract Manufacturing revenue of $4.9 million increased by $3.0 million, or 150%, in fourth quarter fiscal 2013, compared with the same period of the prior year mainly due to the contract manufacturing of TheraSphere® for BTG plc (BTG) subsequent to the sale of the Targeted Therapies business in July 2013.”
    This is noteworthy to ADMD investors in that RadioGel™ will be a competing product, if FDA approved, to TheraSphere®. TheraSphere® is a liver cancer therapy that consists of millions of small glass microspheres (20 to 30 micrometers in diameter) containing radioactive Y-90.
    In addition, Nordian projects that its reactor isotopes revenue will increase by 30% to 40% in fiscal 2014, compared with fiscal 2013.
    This information bodes well for ADMD share price, if RadioGel™ is approve, which I suspect will happen.
    Once the company receives FDA approval for RadioGel™, I’m looking for the market to give the stock a higher price and PE based on the company’s belief “…that its operations could turn cash-positive within four to nine months thereafter and could turn profitable on a GAAP-basis within six to 12 months after clearance is obtained…”

    Below are links from which quotes and information were taken:
    • http://finance.yahoo.com/news/nordion-reports-fourth-quarter-fiscal-120000353.html
    • http://finance.yahoo.com/news/advanced-medical-isotope-corporation-announces-122200915.html

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • MACD...Thanks for link. I have not seen any articles with respect to Y-90 radiogel being used as of yet in hepatic cancer. Currently, TheraSpheres and Y-90 delivered to hepatic tumors via wires and catheters during chemoembolization are well tolerated by patients by personal experience and data.

      Do you forsee the Radiogel being used in a similar fashion? Are there any limitations or pros when used say in the liver as opposed to being needled into the prostate or breast tissue?

      This is def a significant report which shows the potential as the utility of Y-90 is there. Thanks.

 
ADMD
0.0014+0.0003(+27.27%)11:21 AMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.